|
楼主 |
发表于 2011-7-13 15:10:41
|
显示全部楼层
来自: 中国北京
3 处于临床试验阶段的方案
HKI-272是EGFR、HER2及HER3的不可逆抑制剂。体外实验证明HKI-272可抑制对厄罗替尼及吉非替尼产生获得性耐药的H1975细胞株的生长。在体内试验中,HKI-272可使表达L858型EGFR的转基因鼠的肿瘤退缩。
一项临床一期研究表明,HKI-272的最大耐受剂量为320 mg,腹泻是主要的毒副反应及剂量限制性毒性反应。相较于第一代EGFR-TKIs,皮疹并不常见。在入组的12例NSCLC患者,其中5例患者在使用厄罗替尼或吉非替尼进展后,给予HKI-272后疾病稳定了24周。
由美国辉瑞公司研发的新靶向药物crizotinib是一个独特的ALK激酶抑制剂,在携带重组ALK基因的非小细胞肺癌病人中,crizotinib治疗反应率达到90%,但目前只在在约3%到5%的病人中发现ALK基因重组,国外才进入3期临床,目前国内尚无此药。
XL647是EGFR、HER2、VEGFR2、Flt-4及EphB4的抑制剂(Gendreau SB,Ventura R,Keast P,et al.2007)。虽然XL647是类似于吉非替尼及厄罗替尼的可逆性EGFR抑制剂,但由于其对多种受体及其信号通路的抑制作用,我们推测在对第一代EGFR-TKI存在获得性耐药的患者中使用仍能获得部分疗效。尽管机制并不明确,但在体外实验中,我们观察到XL647对H1975细胞株的IC50是厄罗替尼或吉非替尼的1/10。
BIBW2992是EGFR及HER2的不可逆抑制剂,其IC50低于HKI-272。可以与T790M突变了的EGFR结合,所以说它是易瑞沙耐药后的一种选择。对易瑞沙没有产生耐药的病人,用过不可逆抑制剂后再用易瑞沙,只要BIBW2992没有诱导EGFR突变、导致蛋白质结构改变(对BIBW2992耐药),应该没有影响。
XL184 is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2. MET is a receptor tyrosine kinase that plays key roles in cellular proliferation, migration, and invasion as well as angiogenesis1. These biological processes contribute to the transformation, progression, survival and metastasis of cancer cells1. The MET pathway is frequently activated in tumors through MET amplification, mutation, and overexpression, as well as through overexpression of its ligand HGF1. Expression of VEGF has been observed in a variety of cancers and has been associated with the stimulation and growth of new blood vessels to support the tumor2,3. MET and VEGFR2 are important driving forces in angiogenesis, implicated in the ability of tumors to overcome hypoxia following angiogenesis inhibition4,5.
- Motesanib diphosphate
- Necitumumab
- MAGE-A3
- Canfosfamide
- Vadimezan
- PF-299804
- Stimuvax
- Talactoferrin alpha
- Trastuzumab-DM1
- Tivozanib
- brentuximab vedotin
- Ponatinib
- PLX4032
- OncoVex
- vismodegib
|
|